This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

## Rapid Ahalysis of Pseudouridine in Serum of Patients with Chronic Renal Failure, Using Phenylboronic Acid (PBA) Solid-Phase Extraction and HPLC

A. C. Schoots<sup>a</sup>; J. H. M. Peeters<sup>a</sup>

<sup>a</sup> Faculty of Chemical Engineering, SH 2.05, Eindhoven University of Technology, The Netherlands

**To cite this Article** Schoots, A. C. and Peeters, J. H. M.(1990) 'Rapid Ahalysis of Pseudouridine in Serum of Patients with Chronic Renal Failure, Using Phenylboronic Acid (PBA) Solid-Phase Extraction and HPLC', Nucleosides, Nucleotides and Nucleic Acids, 9: 3, 457 — 458

To link to this Article: DOI: 10.1080/07328319008045173 URL: http://dx.doi.org/10.1080/07328319008045173

## PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

RAPID ANALYSIS OF PSEUDOURIDINE IN SERUM OF PATIENTS WITH CHRONIC RENAL FAILURE, USING PHENYLBORONIC ACID (PBA) SOLID-PHASE EXTRACTION AND HPLC.

A.C. Schoots\* and J.H.M. Peeters. Faculty of Chemical Engineering,
SH 2.05, Eindhoven University of Technology, The Netherlands.

Abstract. The rare nucleoside pseudouridine (PSI) was analyzed in sera of endstage renal patients by isocratic HPLC after solid-phase extraction with phenylboronic acid cartridges.

Introduction. Serum concentrations of PSI are elevated in patients with chronic renal failure [1]. Average PSI concentrations in sera of patients treated by CAPD (continuous ambulatory peritoneal dialysis) have been found to be significantly higher as compared to those on regular hemodialysis (94.9  $\mu$ mol/l versus 55.9  $\mu$ mol/l respectively). The reverse was observed for an as-yet unidentified fluorescent compound (denoted UKF3), of which the serum concentration is significantly correlated with that of PSI (r=0.79, P<0.0005; r=0.67, P<0.01, in hemodialysis and CAPD respectively) {2}. It was found that PSI is not significantly bound to serum protein [2]. Three possible causes have been proposed for the high PSI concentrations in CAPD:

1) Low peritoneal permeability of PSI. 2) Specific t-RNA turnover (related to protein synthesis). 3) Asymptomatic peritonitis accompanied by cell-death, or another as-yet-unrecognized cellular process [2].

In order to facilitate the study of the unexpected behavior of PSI in dialysis treatment, we optimized a rapid HPLC-analysis for this compound.

Results. Serum samples were subjected to solid-phase extraction on Bond-Elut<sup>R</sup> silica-bound phenylboronic acid (PBA) cartridges (Analytichem, Harbor City, CA90710, USA), using a Vac-Elut<sup>™</sup> sample station. We optimized the procedure resulting in the following sequence:

- a) wet with 1 ml methanol and 1 ml water;
- b) load cartridge with 250  $\mu$ l serum (buffered to pH 8.6);
- c) wash with 350  $\mu$ l ammoniumacetaat (0.25 mol/1; pH=8.6);
- d) elute with 1 ml formic acid (0.1 mol/1);
- e) inject eluate directly on HPLC; (isocratic 95/5 v/v ammoniumformate buffer(0.05M,pH4)/MeOH, flow 1 ml/min).

Typical chromatograms of (ultrafiltered) uremic serum and an uremic serum PBA-extract are shown in FIG.1.




FIG.1. HPLC chromatograms of ultrafiltered uremic serum (left, gradient elution, conditions see [2,3]), and of an uremic serum PBA-extract (right, isocratic, conditions see text). Equipment for both gradient and isocratic analyses as in [2,3]. 1,creatinine;  $\psi$ ,pseudouridine; 2,uric acid; 3,hypoxanthine; 4,furoylglycine(tent.); 5,p-hydroxyhippuric acid; 6,hippuric acid; a,tyrosine; b,indoxylsulfate; c,tryptophan [4].

TABLE I. Recoveries of the PBA-extraction (mean (S.D.)), n=6.

Analyte	unbuffered serum	buffered serum	buffered aqueous
•			solution (PSI)
PSI	76.7 (4.9)	88.3 (3.3)	97.3 (5.0)
UKF3	96.9 (2.2)	97.8 (3.5)	

Conclusion. Pseudouridine can be analyzed rapidly and reliably by isocratic HPLC after sample pretreatment by PBA solid-phase extraction. Approximately 25 samples can be analyzed daily free from interference by the numerous solutes accumulating in uremic serum. The unknown fluorescent solute "UKF3" probably contains a cis-diol group, which can be concluded from the high recovery on cis-diol specific PBA extraction.

## References.

[1] Asatoor AM. Clin Chim Acta 1968; 20:407-411. [2] Schoots AC, Gerlag PGG, Mulder AW, Peeters JAG, Cramers CAMG. Clin Chem 1988; 34:91-97. [3] Schoots AC, Dijkstra JB, Ringoir SMG, Vanholder R, Cramers CAMG. Clin Chem 1988; 34:1022-1029. [4] Schoots AC, Dissertation, Eindhoven University of Technology, 1988, The Netherlands.